Dias Manuel, Zhang Rui, Lammers Twan, Pallares Roger M
Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
Department of Physics, Faculty of Science, University of Lisbon, Lisboa, 1500-274, Portugal.
Drug Deliv Transl Res. 2025 Mar;15(3):789-797. doi: 10.1007/s13346-024-01716-5. Epub 2024 Oct 8.
Despite being clinically used for over a century, the benefits of silver nanoparticles are perennially under debate and dispute. In the last two decades, a revived interest in their therapeutic applications has resulted in a few new formulations transitioning into clinical trials. These metal nanomedicines are used in concrete applications that are defined by the physicochemical and biological features of the silver nanoconstructs, as well as their biodistribution profiles. Examples of these applications are topical antibacterial and antiviral therapies and wound healing, as these avoid concerns regarding the long-term accumulation of the nanomedicines in fenestrated organs after intravenous administration. Here, we discuss the current landscape of silver nanoparticles, and critically analyze the characteristics that endowed their transition and use in clinical settings.
尽管银纳米颗粒在临床上已使用了一个多世纪，但关于其益处的争论却一直存在。在过去二十年中，人们对其治疗应用重新产生了兴趣，导致一些新制剂进入临床试验阶段。这些金属纳米药物用于具体的应用中，这些应用由银纳米结构的物理化学和生物学特性及其生物分布情况所决定。这些应用的例子包括局部抗菌和抗病毒治疗以及伤口愈合，因为这些应用避免了静脉给药后纳米药物在有窗孔器官中长期积累的问题。在此，我们讨论银纳米颗粒的当前情况，并批判性地分析使其能够在临床环境中实现转化和应用的特性。
